$BRNS
Barinthus Biotherapeutics plc.

2023 Q3 Form 10-Q Financial Statement

#000141057823001666 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $334.0K $17.06M
YoY Change -100.0% -98.04% 48651.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $961.0K $13.13M -$6.445M
YoY Change -108.63% -303.69% -152.1%
% of Gross Profit
Research & Development $15.14M $13.54M $9.720M
YoY Change 55.42% 39.33% 115.57%
% of Gross Profit
Depreciation & Amortization $700.0K $500.0K $992.0K
YoY Change -41.08% -49.6% 853.85%
% of Gross Profit
Operating Expenses $16.11M $26.67M $3.275M
YoY Change -1260.3% 714.38% -80.6%
Operating Profit -$16.11M -$26.34M $13.24M
YoY Change -313.23% -299.0% -178.57%
Interest Expense $189.0K $508.0K $109.0K
YoY Change -73.68% 366.06%
% of Operating Profit 0.82%
Other Income/Expense, Net $1.392M $1.377M $877.0K
YoY Change -23300.0% 57.01% 0.57%
Pretax Income -$14.71M -$24.96M $14.77M
YoY Change -294.95% -268.95% -192.49%
Income Tax -$603.0K -$1.136M -$915.0K
% Of Pretax Income -6.19%
Net Earnings -$14.07M -$23.80M $15.69M
YoY Change -270.74% -251.67% -198.53%
Net Earnings / Revenue -7126.35% 91.97%
Basic Earnings Per Share -$0.37 -$0.62 $0.42
Diluted Earnings Per Share -$0.37 -$0.62 $411.1K
COMMON SHARES
Basic Shares Outstanding 38.52M 38.37M 37.20M
Diluted Shares Outstanding 38.53M 38.41M 38.17M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.3M $173.0M $192.3M
YoY Change -19.89% -10.03% -21.05%
Cash & Equivalents $160.3M $173.0M $192.3M
Short-Term Investments
Other Short-Term Assets $355.0K $1.446M $10.62M
YoY Change 173.08% -86.39% 176916.67%
Inventory
Prepaid Expenses $4.510M $6.762M
Receivables $0.00 $349.0K $17.05M
Other Receivables $5.891M $3.190M $6.295M
Total Short-Term Assets $171.1M $184.8M $226.3M
YoY Change -21.75% -18.35% -11.86%
LONG-TERM ASSETS
Property, Plant & Equipment $12.27M $13.74M $15.38M
YoY Change 81.33% -10.67% 1381.98%
Goodwill $12.21M $12.21M
YoY Change -3.33%
Intangibles $25.90M $26.69M
YoY Change -10.88%
Long-Term Investments
YoY Change
Other Assets $1.055M $1.006M $902.0K
YoY Change 24.56% 11.53% 2718.75%
Total Long-Term Assets $58.91M $61.35M $58.77M
YoY Change 3.6% 4.4% 1789.55%
TOTAL ASSETS
Total Short-Term Assets $171.1M $184.8M $226.3M
Total Long-Term Assets $58.91M $61.35M $58.77M
Total Assets $230.0M $246.1M $285.1M
YoY Change -16.52% -13.66% 9.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.145M $2.429M $4.475M
YoY Change 113.4% -45.72% -4.44%
Accrued Expenses $13.42M $9.682M $7.555M
YoY Change 16.64% 28.15% 107.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $18.57M $12.11M $12.17M
YoY Change 32.34% -0.45% 42.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.278M $1.300M $11.82M
YoY Change 79.75% -89.0% 753.83%
Total Long-Term Liabilities $1.278M $1.300M $11.82M
YoY Change 79.75% -89.0% 753.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.57M $12.11M $12.17M
Total Long-Term Liabilities $1.278M $1.300M $11.82M
Total Liabilities $34.37M $28.67M $30.66M
YoY Change 9.7% -6.49% 208.8%
SHAREHOLDERS EQUITY
Retained Earnings -$159.3M -$145.2M
YoY Change 94.14%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $195.4M $217.2M $254.4M
YoY Change
Total Liabilities & Shareholders Equity $230.0M $246.1M $285.1M
YoY Change -16.52% -13.66% 9.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$14.07M -$23.80M $15.69M
YoY Change -270.74% -251.67% -198.53%
Depreciation, Depletion And Amortization $700.0K $500.0K $992.0K
YoY Change -41.08% -49.6% 853.85%
Cash From Operating Activities -$11.19M -$16.96M -$8.393M
YoY Change -194.17% 102.04% -42.61%
INVESTING ACTIVITIES
Capital Expenditures $36.00K $3.023M -$2.054M
YoY Change -101.5% -247.18% 916.83%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$36.00K -$3.023M -$2.054M
YoY Change -98.22% 47.18% 916.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 46.00K 28.00K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -11.19M -16.96M -8.393M
Cash From Investing Activities -36.00K -3.023M -2.054M
Cash From Financing Activities 46.00K 28.00K 0.000
Net Change In Cash -11.18M -19.95M -10.45M
YoY Change -213.33% 90.98% -111.94%
FREE CASH FLOW
Cash From Operating Activities -$11.19M -$16.96M -$8.393M
Capital Expenditures $36.00K $3.023M -$2.054M
Free Cash Flow -$11.23M -$19.98M -$6.339M
YoY Change -178.57% 215.19% -56.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001828185
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38524059
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38524059
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
37683531
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37683531
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173030000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40367
dei Entity Registrant Name
EntityRegistrantName
VACCITECH PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Unit 6-10, Zeus Building Rutherford Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Harwell
dei Entity Address City Or Town
EntityAddressCityOrTown
Didcot
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX11 0DF
dei City Area Code
CityAreaCode
+44 (0)
dei Local Phone Number
LocalPhoneNumber
1865 818 808
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38524963
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173030000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194385000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
323000
CY2023Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
349000
CY2022Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
5524000
CY2023Q2 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
3137000
CY2022Q4 vacc Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
4541000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8261000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8268000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
184777000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
213041000
CY2023Q2 us-gaap Goodwill
Goodwill
12209000
CY2022Q4 us-gaap Goodwill
Goodwill
12209000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13741000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7957000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26688000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28269000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7707000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7753000
CY2023Q2 us-gaap Other Assets
OtherAssets
1006000
CY2022Q4 us-gaap Other Assets
OtherAssets
976000
CY2023Q2 us-gaap Assets
Assets
246128000
CY2022Q4 us-gaap Assets
Assets
270205000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2429000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3748000
CY2023Q2 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8547000
CY2022Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8061000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1135000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
433000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12111000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12242000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11044000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8340000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2117000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1711000
CY2023Q2 vacc Deferred Tax Liability Net
DeferredTaxLiabilityNet
2094000
CY2022Q4 vacc Deferred Tax Liability Net
DeferredTaxLiabilityNet
3746000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1300000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
965000
CY2023Q2 us-gaap Liabilities
Liabilities
28666000
CY2022Q4 us-gaap Liabilities
Liabilities
27004000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000025
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38524059
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37683531
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
385636000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
379504000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145225000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103243000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-23289000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-33460000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
217209000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
242896000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
253000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
305000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
217462000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
243201000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246128000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
270205000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
334000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17063000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
802000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32081000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13543000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9720000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23357000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20421000
CY2023Q2 vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
13128000
CY2022Q2 vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
-5892000
vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
25266000
vacc General And Administrative Income Expense
GeneralAndAdministrativeIncomeExpense
-2156000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26671000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3828000
us-gaap Operating Expenses
OperatingExpenses
48623000
us-gaap Operating Expenses
OperatingExpenses
18265000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26337000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
13235000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47821000
us-gaap Operating Income Loss
OperatingIncomeLoss
13816000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
522000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
669000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2110000
us-gaap Investment Income Interest
InvestmentIncomeInterest
752000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-7000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-14000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-8000
CY2023Q2 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
559000
CY2022Q2 vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
826000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1716000
vacc Research And Development Incentive Income Expense
ResearchAndDevelopmentIncentiveIncomeExpense
1874000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
310000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
310000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1377000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1539000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4122000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2669000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24960000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14774000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43699000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16485000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1136000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-915000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1652000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1778000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23824000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
15689000
us-gaap Profit Loss
ProfitLoss
-42047000
us-gaap Profit Loss
ProfitLoss
18263000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-22000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-65000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23802000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
15693000
us-gaap Net Income Loss
NetIncomeLoss
-41982000
us-gaap Net Income Loss
NetIncomeLoss
18289000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38407672
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37202600
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38211625
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37196843
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38407672
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38174426
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38211625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38260579
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23824000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
15689000
us-gaap Profit Loss
ProfitLoss
-42047000
us-gaap Profit Loss
ProfitLoss
18263000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5604000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16807000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10184000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22790000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-18220000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1118000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-31863000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4527000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-15000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-34000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-52000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-71000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18205000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1084000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31811000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4456000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
243201000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2222000
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1789000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4580000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-18223000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
233569000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1990000
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
123000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5604000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23824000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
217462000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
252562000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3984000
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5983000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2574000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
253137000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194385000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214054000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173030000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192327000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2748000
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16807000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
15689000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
254767000
us-gaap Profit Loss
ProfitLoss
-42047000
us-gaap Profit Loss
ProfitLoss
18263000
us-gaap Share Based Compensation
ShareBasedCompensation
4212000
us-gaap Share Based Compensation
ShareBasedCompensation
6732000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2520000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1958000
vacc Non Cash Lease Expenses
NonCashLeaseExpenses
595000
vacc Non Cash Lease Expenses
NonCashLeaseExpenses
528000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-7122000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
18730000
us-gaap Interest Expense
InterestExpense
14000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
309000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
626000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1652000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1778000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5606000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17028000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3107000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6020000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-1586000
vacc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-388000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1916000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
776000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
275000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-488000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-138000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20131000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14972000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5530000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3146000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5530000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3146000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1880000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
163000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
159000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1717000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-159000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2589000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3450000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21355000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21727000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
506000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1719000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2400000
vacc Asset Retirement Obligations
AssetRetirementObligations
282000
vacc Asset Retirement Obligations
AssetRetirementObligations
826000
CY2023Q2 vacc Changes To Right Of Use Asset Resulting From Lease Reassessment Event
ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent
-47000
CY2022Q2 vacc Changes To Right Of Use Asset Resulting From Lease Reassessment Event
ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent
-46000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue, and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p>
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8268000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7700000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
20500000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23824000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
15689000
us-gaap Profit Loss
ProfitLoss
-42047000
us-gaap Profit Loss
ProfitLoss
18263000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-22000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-65000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23802000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
15693000
us-gaap Net Income Loss
NetIncomeLoss
-41982000
us-gaap Net Income Loss
NetIncomeLoss
18289000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38407672
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37202600
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38211625
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37196843
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
971826
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1063736
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38407672
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38174426
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38211625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38260579
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2023Q2 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
900000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
400000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2023 vacc Estimated Amortization Expense Of Intangible Assets
EstimatedAmortizationExpenseOfIntangibleAssets
3100000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6762000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5887000
CY2023Q2 vacc Employee Retention And Payroll Tax Credit Current
EmployeeRetentionAndPayrollTaxCreditCurrent
53000
CY2022Q4 vacc Employee Retention And Payroll Tax Credit Current
EmployeeRetentionAndPayrollTaxCreditCurrent
48000
CY2022Q4 vacc Lease Incentive Receivables Current
LeaseIncentiveReceivablesCurrent
1770000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1446000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
563000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8261000
CY2023Q2 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
3708000
CY2022Q4 vacc Accrued Manufacturing And Clinical Expenses Current
AccruedManufacturingAndClinicalExpensesCurrent
2997000
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
29000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
9000
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1178000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1925000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
374000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
928000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2620000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1270000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
638000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
932000
CY2023Q2 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8547000
CY2022Q4 vacc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8061000
CY2023Q2 vacc Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q2 vacc Percentage Of Shares Necessary To Exercise Preemptive Rights
PercentageOfSharesNecessaryToExercisePreemptiveRights
0.75
vacc Period Of Preemptive Rights To Be Exercised
PeriodOfPreemptiveRightsToBeExercised
P5Y
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1990000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2748000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4212000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6732000
CY2021Q3 vacc Number Of Square Feet Under Lease Agreement
NumberOfSquareFeetUnderLeaseAgreement
31000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7707000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7753000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1135000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
433000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11044000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8340000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y5M8D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
us-gaap Short Term Lease Cost
ShortTermLeaseCost
303000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
529000
us-gaap Operating Lease Payments
OperatingLeasePayments
442000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1081000
CY2023Q2 vacc Lessee Operating Lease Receivable Remainder Of Fiscal Year
LesseeOperatingLeaseReceivableRemainderOfFiscalYear
321000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1782000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1934000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1958000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1983000
CY2023Q2 vacc Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
10002000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17338000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5159000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12179000

Files In Submission

Name View Source Status
0001410578-23-001666-index-headers.html Edgar Link pending
0001410578-23-001666-index.html Edgar Link pending
0001410578-23-001666.txt Edgar Link pending
0001410578-23-001666-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vacc-20230630.xsd Edgar Link pending
vacc-20230630x10q.htm Edgar Link pending
vacc-20230630x10q001.jpg Edgar Link pending
vacc-20230630xex31d1.htm Edgar Link pending
vacc-20230630xex31d2.htm Edgar Link pending
vacc-20230630xex32d1.htm Edgar Link pending
vacc-20230630_def.xml Edgar Link unprocessable
vacc-20230630_lab.xml Edgar Link unprocessable
vacc-20230630_pre.xml Edgar Link unprocessable
vacc-20230630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vacc-20230630_cal.xml Edgar Link unprocessable